HER2+ 유방암

Docetaxel (Docetaxel, Docetaxel (T) + bevacizumab)

Breast Cancer · Breast Cancer

AntibodystaleHenan Cancer HospitalPhase 3

trastuzumab (Herceptin, Docetaxel+ carboplatin+ trastuzumab + patuzumab)

Breast Cancer,HER2-positive · HER2

#HER2#Antibody#Phase3#항체#면역항체+4

AntibodystaleCancer Trials IrelandPhase 2

trastuzumab (Herceptin, Docetaxel, Carboplatin and Trastuzumab)

Breast Cancer · Breast Cancer

AntibodystaleCancer Trials IrelandPhase 2

trastuzumab (Herceptin, Docetaxel, Carboplatin, Trastuzumab and Lapatinib)

Breast Cancer · Breast Cancer

AntibodystaleAuxilio Mutuo Cancer CenterPhase 2

trastuzumab (Herceptin, Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab)

Infiltrating Duct and Lobular Carcinoma In Situ; Invasive Lobular Breast Carcinoma · Infiltrating Duct and Lobular Carcinoma

#InfiltratingDuctandLobularCarcin#Antibody#Phase2#항체#면역항체+3

trastuzumab (Herceptin, TCH, Docetaxel, carboplatin, trastuzumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab)

Breast Cancer · Breast Cancer

Docetaxel, doxorubicin, cyclophosphamide (TAC, Docetaxel, doxorubicin, cyclophosphamide, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab)

Breast Cancer · Breast Cancer

Doxorubicin and cyclophosphamide (AC, Doxorubicin and cyclophosphamide, Doxorubicin and cyclophosphamide (AC) + bevacizumab)

Breast Cancer · Breast Cancer

CGTBiologicstaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#세포유전치료#CAR-T+4

CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+5

AntibodystaleKyoto Breast Cancer Research Ne…Phase 2

Durvalmab&Tremelimumab&Fulvestrant (Durvalmab&Tremelimumab&Fulvestrant)

Breast Cancer · Breast Cancer

ADCBiologicstaleFudan UniversityPhase 2

임상시험 1상태 DISCONTINUED

E1: SHR-A1811 (E1: SHR-A1811)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

ADCBiologicstaleFudan UniversityPhase 2

E2: SHR-A1811 with everolimus (E2: SHR-A1811 with everolimus)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

CGTBiologicstaleSecond Affiliated Hospital of G…Phase 1

EGFR/B7H3 CAR-T (EGFR/B7H3 CAR-T)

EGFR/ B7H3-positive Advanced Lung Cancer; EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3

CGTBiologicstaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#세포유전치료#CAR-T+5

ADCBiologicstaleInstitut CuriePhase 3

Endocrine therapy combined with the local treatment of FES-negative lesions (Endocrine therapy combined with the local treatment of FES-negative lesions)

Breast Carcinoma · Breast Carcinoma

#BreastCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1

AntibodystaleSun Yat-sen UniversityPhase 3

trastuzumab (Herceptin, Endocrine therapy combined with trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#항체#면역항체+2

ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 2

Endoxifen + Abemaciclib (Endoxifen + Abemaciclib)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

AntibodystaleTianjin Medical University Canc…Preclinical

Enituzumab injection+Abesili tablets+Anastrozole tablets (Enituzumab injection+Abesili tablets+Anastrozole tablets)

Advanced HR+ HER2 Negative Breast Carcinoma · HER2

#HER2#Antibody#Preclinical#항체#면역항체+3